COLY-MYCIN S OTIC Rx
Generic Name and Formulations:
Colistin (as sulfate) 3mg, neomycin (as sulfate) 3.3mg, hydrocortisone acetate 10mg, thonzonium bromide 0.5mg; per mL; otic susp; contains thimerosal.
Indications for COLY-MYCIN S OTIC:
Susceptible infections of the external auditory canal, mastoidectomy, fenestration cavities.
Clean and dry ear. 5 drops (using calibrated dropper), or 4 drops (using dropper bottle) in ear(s) 3 or 4 times daily; max 10 days. May substitute saturated cotton wick moistened every 4 hours; replace at least every 24 hrs.
Clean and dry ear. 4 drops (using calibrated dropper), or 3 drops (using dropper bottle) in ear(s) 3 or 4 times daily; max 10 days. May substitute saturated cotton wick moistened every 4 hours; replace at least every 24 hrs.
Viral infections of the ear (e.g., herpes simplex, vaccinia, varicella).
Perforated eardrum. Chronic otitis media. Reevaluate if no improvement in 1 week. Discontinue if local irritation or sensitization occurs.
Antibiotics + steroid + surfactant.
Susp—5mL (w. dropper)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC